Cell Therapy Ltd finishes record breaking crowdfunding campaign

Cell Therapy Ltd has this week ended its crowdfunding campaign with Crowdcube, gathering a record breaking grand total of £691,000 through 306 investors.

  • Initial target £250,000
  • Value raised ends at 277% of initial target
  • Funds raised in two weeks

With the additional investors on board CTL are hosting a function in London on Wednesday 10th December to allow selected investors to meet key figures behind CTL, with Sir Martin Evans and Executive Director Mr Ajan Reginald in attendance.

Advertisements

The Times Newspaper reports Lord Jones joins Cell Therapy Ltd and leads innovative crowdfunding initiative

Well known business advisor Lord Digby Jones who personally invested in Cell Therapy Ltd and was recently appointed Vice-Chairman of CTL, spoke to the times newspaper recently about his expectations for the difference that HeartcelTM will make.

Read below for the full article:

Digby Article picture jpeg

Is Crowdfunding the new alternative funding option for Biotech?

We’re pleased to announce CTL’s Executive Director Mr Ajan Reginald will be part of a free live webinair discussion on “21st century funding strategies for 21st century medicines” alongside Michael Wilkinson, Head of Investments at Crowdcube and Mark Beards, Director of Healthcare and Lifescience at KPMG. The Webinar will take place on Monday December 8th 2014 3:00 PM – 4:00 PM GMT. The online discussion will be exploring Crowd equity funding as the new alternative and innovative funding option for Biotech companies, primarily looking at how it is possible to complete clinical trials with private funding and no VC money.

Mr Reginald will be a key figure in the discussion having recently launched a successful crowdfunding campaign using Crowdcube, reaching and surpassing an ambitious fundraising target of £250,000 in less than a week.

Please follow the below link to register for the free event:

http://biotechandmoney.hs-sites.com/crowdfunding-webinar

Cell Therapy Ltd hits Crowdfunding Target in Record Time

Cell Therapy Ltd’s crowdfunding campaign has successfully funded and reached 100% target on Crowdcube, the world’s leading investment crowdfunding platform.

After less than one week CTL managed to exceed their £250,000 target, an indication of the level of support for their breakthrough UK science and world-class team.

The company aims to utilise the money raised to support the development and final-stage testing of its innovative new medicine HeartCel™, that uses adult stem cells to treat heart failure. No current medications exist that can regenerate the heart in the growing $50bn global heart failure market.

CTL’s Executive Director and Co-founder Ajan Reginald will be delivering a pitch at an Investor Evening hosted by Crowdcube on Wednesday 3rd December at the Institute of Contemporary Arts in London.

Ajan Reginald, Executive Director Cell Therapy Ltd

Mr Ajan Reginald, Ex- Global Head of Emerging Technologies and Ex-Business Development Director at Roche Pharmaceuticals, Co-founded Cell Therapy Ltd with Sir Martin Evans in 2009.

To register of the event: http://bit.ly/1yOkUUs

For further updates on CTL be sure to follow us on twitter:

@CellTherapyLtd

Nobel Laureate’s Stem cell company using Crowdfunding to Repair Broken Hearts

Nobel Laureate Prof. Sir Martin Evans (2007 Nobel Laureate in Medicine) is using Crowdcube, the world’s first and most successful investment crowdfunding platform to Repair Broken Hearts. Founded in 2009 by Sir Martin, Cell Therapy Limited produces a regenerative medicine, Heartcel™ using adult stem cells to treat heart failure. Heartcel™ regenerates the heart reducing the size of the scar, restoring heart function through heart regeneration. CTL plans to launch Heartcel™ in 2016.

Current investors of CTL include Lord Digby Jones (former Director General of CBI) and Rhodri Morgan (Ex-First Minister of Wales). The two have taken active director positions, citing CTLs combination of breakthrough UK science and world-class team as motivations. CTL’s Crowdcube campaign went live on Tuesday 25th of November 2014.

Crowdcube enables SME’s to bypass the traditional business angel, VC or bank finance routes, giving them more control and access to more investors. Since 2011, more than 110,000 investors have registered with Crowdcube, helping to raise over £47 million of equity finance for 165 British business. Support behind the program is evident, as the company has already attracted over fifty investors and has raised £130,000 of its £250,000 target in less than twenty-four hours.

crowdcube_1

For information on investment opportunities visit:  www.crowdcube.com

Cell Therapy Ltd releases new HeartCel™ “Repairing Broken Hearts” info-graphic site

In anticipation of CTL’s investment campaign using Crowdcube, the world’s largest investment crowdfunding platform, CTL has launched a new website to highlight their innovative new therapy, HeartCel™.

The info-graphic site provides an overview of the causes of heart failure that effects more than 20 million people and is the leading cause of mortality worldwide. HeartCel™ is a novel stem cell therapy that can regenerate the heart following heart failure, no current medications can regenerate the heart. HeartCel™ has the potential to help millions of patients every year in the Global Heart Failure Market, currently valued at over $50bn and growing.

For further details on the product and investment opportunities, visit the website itself at     http://www.heartcel.com/

Lord Digby Jones joins Nobel Laureate in British Biotech Company: Cell Therapy Ltd

        Lord Digby Jones has joined with Nobel Laureate Professor Sir Martin Evans (2007 Nobel Laureate in Medicine) at Cell Therapy Limited (CTL). Cell Therapy Limited produces a regenerative medicine, Heartcel™ using adult stem cells to treat heart failure. More than 20 million people suffer from heart failure, making it the leading cause of mortality worldwide.

       Heart failure can develop after a heart attack or when the arteries to the heart are constricted, resulting in scarring of the heart muscle. Unfortunately no current medications can regenerate the heart, however Heartcel™ can as it regenerates the heart reducing the size of the scar, restoring normal heart function through heart regeneration.  CTL plans to launch Heartcel™ in 2016. Lord Jones first invested in CTL and now joins as a non-executive Director, citing CTL’s combination of breakthrough science and a world-class team in a UK company as his motivation.

“Cell Therapy combines cutting edge technology and a world-class team to solve a global issue – heart failure.  British innovation at its best”

“Cell Therapy combines cutting edge technology and a world-class team to solve a global issue – heart failure. British innovation at its best”

Lord Digby Jones is a British businessman, broadcaster and corporate advisor. Former Director General of the Confederation of British Industry (CBI) and UK Minister of State for Trade and Investment.  He was noted as one of the CBI’s most successful and high-profile leaders.  After his tenure he has gone on to advise companies including JCB, Jaguar cars, BP, Triumph Motorcycles, AON, Babcock and Unipart.

For further information please contact: Ajan Reginald – Executive Director                                Email: Ajan@Celltherapyltd.com // T: +447956455046

Cell Therapy Limited (CTL): www.celltherapyltd.com                                                                   Heartcel: www.heartcel.com